Assisted Reproductive Technology Market Report 2024-2033: Vitrolife Leads the Competition with 9.8% Share, Followed by Ferring, and Progyny
Global Assisted Reproductive Technology Market
Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Assisted Reproductive Technology Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.
The global assisted reproductive technology market reached a value of nearly $37.6 billion in 2023, having grown at a compound annual growth rate (CAGR) of 5.6% since 2018. The market is expected to grow from $37.6 billion in 2023 to $55.91 billion in 2028 at a rate of 8.3%. The market is then expected to grow at a CAGR of 8.4% from 2028 and reach $83.8 billion in 2033.
Where is the largest and fastest-growing market for assisted reproductive technology? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider assisted reproductive technology market; and compares it with other markets.
Growth in the historic period resulted from the increasing prevalence of PCOS (polycystic ovary syndrome), growing trend of late parenthood, increase in same-sex couples, rise in male infertility and increased healthcare expenditure. Factors that negatively affected growth in the historic period were high cost of fertility services and low success rates of IVF.
Going forward, the technological developments, growing prevalence of obesity, rising number of infertility cases, increasing government initiatives and funding and rise in disposable income will drive the market. Factors that could hinder the growth of the assisted reproductive technology market in the future include stringent government policies and high cost of treatment.
Market Insights
The assisted reproductive technology (ART) market is segmented by technology into in vitro-fertilization (IVF), artificial insemination (AI-IUI) and other technologies. The in vitro-fertilization (IVF) market was the largest segment of the assisted reproductive technology (ART) market segmented by technology, accounting for 83.2% or $26.12 billion of the total in 2023. Going forward, the artificial insemination (AI-IUI) segment is expected to be the fastest growing segment in the assisted reproductive technology (ART) market segmented by technology, at a CAGR of 10.4% during 2023-2028.
The assisted reproductive technology (ART) market is segmented by procedure type into fresh non-donor, fresh donor, frozen donor, frozen non-donor and embryo or egg banking. The fresh non-donor market was the largest segment of the assisted reproductive technology (ART) market segmented by procedure type, accounting for 48.5% or $15.22 billion of the total in 2023. Going forward, the embryo or egg banking segment is expected to be the fastest growing segment in the assisted reproductive technology (ART) market segmented by procedure type, at a CAGR of 10.7% during 2023-2028.
The assisted reproductive technology market is segmented by end-user into hospitals, fertility clinics and other end-users. The fertility clinics market was the largest segment of the assisted reproductive technology market segmented by end-user, accounting for 48% or $18.06 billion of the total in 2023. Going forward, the fertility clinics segment is expected to be the fastest growing segment in the assisted reproductive technology market segmented by end-user, at a CAGR of 9% during 2023-2028.
The assisted reproductive technology (ART) testing market is segmented by ART testing/diagnosis into in ovulation testing, hysterosalpingography, ovarian reserve testing, genetic testing and other tests. The other tests market was the largest segment of the assisted reproductive technology (ART) testing market segmented by ART testing/diagnosis, accounting for 33.3% or $2.07 billion of the total in 2023. Going forward, the other tests segment is expected to be the fastest growing segment in the assisted reproductive technology (ART) testing market segmented by ART testing/diagnosis, at a CAGR of 6.6% during 2023-2028.
The other tests market is segmented by ART diagnosis/testing into in computer assisted semen analysis (CASA), sperm penetration assay, microscopic examination and others testing/diagnosis. The computer assisted semen analysis (CASA) market was the largest segment of the assisted reproductive technology market segmented by ART testing/diagnosis, accounting for 52.4% or $1.08 billion of the total in 2023. Going forward, the sperm penetration assay segment is expected to be the fastest growing segment in the assisted reproductive technology market segmented by ART testing/diagnosis, at a CAGR of 8.5% during 2023-2028.
North America was the largest region in the assisted reproductive technology market, accounting for 34.9% or $10.95 billion of the total in 2023. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, the fastest-growing regions in the assisted reproductive technology market will be Asia-Pacific and North America, where growth will be at CAGRs of 6.4% and 6.1% respectively. These will be followed by Western Europe and South America, where the markets are expected to grow at CAGRs of 5.6% and 5.3% respectively.
The global assisted reproductive technology market is fairly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up to 17.9% of the total market. Vitrolife was the largest competitor with a 9.8% share of the market, followed by Ferring B.V. with 3.7%, Progyny Inc. with 1.5%, CooperSurgical Inc. with 1.2%, FUJIFILM Irvine Scientific, Inc. with 1.1%, Monash IVF Group with 0.4%, Hamilton Thorne Inc. with 0.2%, Genea Limited with 0.1%, IVI-RMA with 0.01% and Bloom IVF Centre with 0.01%.
The top opportunities in the assisted reproductive technology (ART) market segmented by technology will arise in the in vitro-fertilization (IVF) segment, which will gain $13.22 billion of global annual sales by 2028. The top opportunities in the assisted reproductive (ART) technology market segmented by procedure type will arise in the fresh non-donor segment, which will gain $8.01 billion of global annual sales by 2028. The top opportunities in the assisted reproductive technology market segmented by end-user will arise in the fertility clinics segment, which will gain $9.73 billion of global annual sales by 2028. The top opportunities in the assisted reproductive technology (ART) testing market segmented by ART testing/diagnosis will arise in the other tests segment, which will gain $785.5 million of global annual sales by 2028. The top opportunities in the other tests market segmented by ART testing/diagnosis will arise in the computer assisted semen analysis (CASA) segment, which will gain $430.6 million of global annual sales by 2028. The assisted reproductive technology market size will gain the most in the USA at $4.55 billion.
Market-trend-based strategies for the assisted reproductive technology market include key players launching innovative programs to promote art and support sustainability, impact of artificial intelligence on assisted reproductive technology, advanced technological solutions in assisted reproductive technology, blockchain integration in assisted reproductive technology, strategic collaborations driving innovation in assisted reproductive technology and innovative fertility treatment options to enhance access to care.
Player-adopted strategies in the assisted reproductive technology market include focus on expanding business expertise through strategic acquisitions and strategic partnerships, strengthening business capabilities through new product platforms, enhancing business operations through new product developments and strengthening business capabilities through new product launches.
Markets Covered:
1) by Technology: In Vitro-Fertilization (IVF); Artificial Insemination (AI-IUI); Other Technologies
2) by Procedure Type: Fresh Non-Donor; Fresh Donor; Frozen Donor; Frozen Non-Donor; Embryo or Egg Banking
3) by End-user: Hospitals; Fertility Clinics; Other End-users
4) by Testing/Diagnosis: In Ovulation Testing; Hysterosalpingography; Ovarian Reserve Testing; Genetic Testing; Other Tests
Key Companies Mentioned: Vitrolife; Ferring B.V.; Progyny Inc.; CooperSurgical Inc.; FUJIFILM Irvine Scientific, Inc.
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; assisted reproductive technology indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Key Attributes
Report Attribute | Details |
No. of Pages | 393 |
Forecast Period | 2021 - 2031 |
Estimated Market Value (USD) in 2021 | $37.6 Billion |
Forecasted Market Value (USD) by 2031 | $83.8 Billion |
Compound Annual Growth Rate | 8.3% |
Regions Covered | Global |
A selection of other major companies mentioned in this report includes, but is not limited to:
Monash IVF Group
Hamilton Thorne Inc.
Genea Limited
IVI-RMA
Bloom IVF Centre
Jinxin Fertility Group Limited
Amcare
Beijing United Family Hospital
Reproductive & Genetic Hospital CITIC-XIANGYA
OvaScience Shanghai
Shanghai Ji Ai Genetics & IVF Institute
Guangzhou Women and Children's Medical Center
Shenzhen Zhongshan Urology Hospital
Shanghai Ninth People's Hospital
Nova IVI Fertility
Manipal Fertility
Indira IVF
Milann
Origio Japan K.K
Eizai
Konica Minolta Healthcare
Fuso Pharmaceutical Industries, Ltd
Tokai Hit
IVF Korea
CHA Fertility Center
Fertility Center of CHA Gangnam Medical Center
Virtus Health
Fertility First
Queensland Fertility Group
Morula IVF
PrimaNest
Hermina IVF Center
Fertility Clinic Jakarta
EUGIN Group
Clinique de la Muette
FIV Paris-Nord
IVI Clinic
Groupe NATEC Medical
Medistim
Medfem Clinic
StorkKlinik
Fertility Center Berlin
Barcelona IVF
Instituto Bernabeu
Ginemed
Livio Fertilitetscentrum
Stockholm IVF
Gothenburg University Hospital
Vasteras Hospital
Uppsala University Hospital
Fertility Clinic GENEVA
Swiss Fertility Center
Kinderwunschzentrum Zurich
Basel Fertility Clinic
Lausanne Fertility Clinic
Reprogenetics Italia
Bologna Fertility Center
Roma Fertility Clinic
Naples Fertility Clinic
Milan Fertility Clinic
Care Fertility Group
The Lister Fertility Clinic
Create Fertility
London Women's Clinic
Manchester Fertility
European Medical Center (EMC)
Nova Clinic
IVI Russia
MD Medical Group
Mother and Child
MedLife
Regina Maria
Fertilia Clinic
Biogenis Clinic
Genesys Fertility Center
INVICTA Fertility Clinics
InviMed
Gyncentrum
VitroLive
Fertility Clinic AVA
IVF Cube
Prague Fertility Centre
IVF Zlin
IVF ReproGenesis
Fertimed
Future Fertility
IVI RMA
US Fertility LLC
Ovation Fertility
INVO Bioscience Inc.
Wisconsin Fertility Institute
Alife Health
Cook Medical
Shady Grove Fertility
Cooper Surgical Inc.
FertGroup
Huntington Medicina Reprodutiva
San Isidro Medicina
Fertipraxis
Oya Care
AIVF
Gargash Hospital
Medfem Fertility Clinic
VitaLab Fertility Clinic
Cape Fertility Clinic
Fertility Clinic Johannesburg
Sandton Fertility Clinic
The Bridge Clinic
George's Memorial Medical Centre
Mart Life Detox Clinic
Rivers State University Teaching Hospital (RSUTH)
St. Ives Specialist Hospital
Nairobi IVF Centre
Avenue Healthcare Fertility Centre
Mediheal Group of Hospitals
The Nairobi Hospital
Family Fertility Centre
Fertility Options
IVF Uganda
Women's Hospital International and Fertility Centre
Dr. Salah Dawood Clinic
Cairo Fertility Clinic
Nile Fertility Center
Assiut University Hospital
Alfa Medical Centre
For more information about this report visit https://www.researchandmarkets.com/r/6gzy3t
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900